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each year around the world, both directly and indirectly. Vi-
ruses interfere with many cell functions, particularly critical
pathways for cell death, by affecting various intracellular medi-
ators. MicroRNAs (miRNAs) are a major example of these me-
diators because they are involved in many (if not most) cellular
mechanisms. Virus-regulated miRNAs have been implicated in
three cell death pathways, namely, apoptosis, autophagy, and
anoikis. Several molecules (e.g., BECN1 and B cell lymphoma
2 [BCL2] family members) are involved in both apoptosis
and autophagy, while activation of anoikis leads to cell death
similar to apoptosis. These mechanistic similarities suggest
that common regulators, including some miRNAs (e.g., miR-
21 and miR-192), are involved in different cell death pathways.
Because the balance between cell proliferation and cell death is
pivotal to the homeostasis of the human body, miRNAs that
regulate cell death pathways have drawn much attention from
researchers. miR-21 is regulated by several viruses and can
affect both apoptosis and anoikis via modulating various tar-
gets, such as PDCD4, PTEN, interleukin (IL)-12, Maspin, and
Fas-L. miR-34 can be downregulated by viral infection and
has different effects on apoptosis, depending on the type of vi-
rus and/or host cell. The present review summarizes the exist-
ing knowledge on virus-regulated miRNAs involved in the
modulation of cell death pathways. Understanding the mecha-
nisms for virus-mediated regulation of cell death pathways
could provide valuable information to improve the diagnosis
and treatment of many viral diseases.University of Medical Sciences, Tehran, Iran.
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Virus infections have long posed a threat to human public health.
Although virus-related deaths have sharply declined during the pastMolecular T
This is an open access article under tcentury,1 the death toll is still relatively high. According to the World
Health Organization (WHO), respiratory diseases linked to seasonal
influenza lead to 650,000 deaths each year. Most recently, the ongoing
pandemic of coronavirus disease 2019 (Covid-19) has officially been
responsible for 1.6 million deaths so far (December 12, 2020). Addi-
tionally, viruses are indirectly involved in other lethal diseases; for
instance, 15% of human cancer deaths are estimated to be associated
with a viral infection.2
Over the whole range of viruses, from small RNA viruses (e.g., dengue
virus [DENV]) to large DNA viruses (e.g., poxviruses), viruses
uniquely manipulate the host cell machinery in order to facilitate
the pathogenic process.3 Cell death pathways in particular have
been shown to be strongly affected by viral infections. Because a
marked imbalance between the rate of cell proliferation and cell death
is associated with serious diseases such as cancer,4 dysregulation of
cell death pathways, whether caused by a virus or other factors, is
of great importance. Several factors associated with modulation of
cell death pathways (e.g., autophagy-related genes5 and survivin6)
have been shown to be dysregulated in virus-infected cells. One ofherapy: Nucleic Acids Vol. 24 June 2021 ª 2021 The Author(s). 487
he CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Reviewthe major molecular controllers of cell death is microRNAs (miR-
NAs), which can be affected by viral infections.
miRNAs are small non-coding RNAs that recognize and bind to the 30
untranslated region (UTR) of messenger RNAs (mRNAs) that code
for cellular proteins, in order to block the translation of the target pro-
tein or, to a lesser extent, degrade the mRNA.7–10 miRNAs are key
modulators of many fundamental cellular processes, including
cellular metabolism, proliferation, and cell death in a variety of cell
types, such as stem cells, immune cells, cancer cells, and especially vi-
rus-infected cells.7,11–14 Hence, the virus-modulated expression of
miRNAs that can result in the regulation of cell death pathways
may explain the pathogenesis and lead to the possible treatment of
viral diseases.
Viruses can affect cell death pathways by the deregulation of miRNAs,
leading to interference with apoptotic and autophagic mechanisms, as
shown in Figures 1 and 2. In the present review we summarize the ef-
fects of viruses on various miRNAs involved in the regulation of
different cell death pathways, including apoptosis, autophagy, and
anoikis.
Apoptosis
The apoptosis pathways differ between normal cells and cancer cells
and even between different cancer cell lines, making the design of
therapeutic approaches based on apoptosis induction somewhat chal-
lenging.17,18 Therefore, these studies, which were fully focused on
apoptosis, have been recently expanded to cover other cell death path-
ways, i.e., autophagy and anoikis.19 Exploring the cell death pathways
and their mechanistic regulation may allow advances to be made in
the diagnosis and treatment of several diseases.
Derived from the Greek root “apo” plus “ptosis,”meaning “falling off”
(such as leaves falling off a tree),20 the term apoptosis refers to pro-
grammed cell death type I that has been long regarded as the main
mechanism of controlled cell death.21 Apoptotic cell death is charac-
terized by certain morphological features and some enzymatic pro-
cesses occurring within the cell, which are designed to allow the
removal of unneeded or defective cells without any significant risks
for the surrounding tissues.20
Researchers have divided apoptotic pathways into two broad classes,
the intrinsic (mitochondrial) pathway and the extrinsic pathway (i.e.,
death receptor and the perforin/granzyme pathways) (Figure 3).
Therefore, the extrinsic signaling pathway involves the tumor necro-
sis factor (TNF) receptor gene superfamily, and the intrinsic signaling
pathway involves many components that can have a negative or pos-
itive effect on apoptosis. Apoptosis can be triggered by negative sig-
nals arising from the lack of certain growth factors, cytokines, and
hormones. The mitochondrial membrane is influenced by such
changes and thus the mitochondrial apoptosis pathway is activated.
The control and regulation of mitochondrial apoptosis requires a bal-
ance between anti-apoptotic as well as pro-apoptotic members of the
B cell lymphoma 2 (Bcl-2) protein family. Additionally, the inhibitor488 Molecular Therapy: Nucleic Acids Vol. 24 June 2021of apoptosis (IAP) family consisting of baculoviral IAP repeat-con-
taining (BIRC) proteins has been found to be a major regulator of
apoptosis, because these proteins affect both the intrinsic and
extrinsic pathways.22
Both of these initial pathways (intrinsic and extrinsic) initiate the
executioner (secondary) pathway of apoptosis through different,
but related, routes. Both initial and executioner pathways of apoptosis
are highly dependent on a family of cysteine-aspartic acid proteases
called caspases. Caspases are divided into two groups, i.e., initiator
or executioner, according to the pathway in which they partici-
pate.23,24 After detection of cell damage, procaspases are converted
into the active initiator caspases (caspase-8 from the extrinsic
pathway, and caspase-9 from the intrinsic pathway), which, in turn,
activate the executioner caspases (caspase-3, -6, and -7). Once acti-
vated, the executioner caspases embark on a consecutive series of
steps that culminate in DNA fragmentation. These steps include
endonuclease activation, degradation of the nuclear proteins and
cytoskeleton, protein cross-linking, the expression of ligands designed
to attract phagocytes, and the formation of apoptotic bodies.24,25 The
apoptotic bodies, which contain the potentially pathogenic remnants
of cellular contents, will be further removed mainly by
macrophages.20
Normal levels of apoptosis are required not only for cellular and or-
gan homeostasis, but can also inhibit carcinogenesis.26,27 Apoptosis
plays a major role in modulating multiple cellular processes such as
the appropriate function and development of the immune system,
hormone-regulated atrophy, embryonic development, cell recycling,
and cell death in response to toxic stimuli.24 Activation of apoptosis
irreversibly triggers efficient and rapid cell death through mitochon-
drial membrane permeabilization and caspase activation.28,29 The
downregulation of apoptosis in cancer cells not only increases the
proliferation rate, but it prolongs the survival time of the cancer cells
through multiple pathways. Moreover, resistance of the malignant
cells to apoptosis leads to several consequences, such as oncogene
activation, metabolic stress, lack of blood supply, nutrient and growth
factor depletion, tolerance to hypoxia, and failure of treatment inter-
ventions.28,30 In addition to cancer cells, virus-infected cells such as
those infected with hepatitis B virus (HBV)31 or Epstein-Barr virus32
show resistance to apoptosis activation.
Autophagy
Autophagy is mainly a cytoprotective process designed to protect
against starvation, in which cytoplasmic components undergo seques-
tration, autophagosomal transport to lysosomes, and subsequent
degradation33–35 (Figure 4). It is notable that lysosomes have the ability
to digest these components, which can then be recycled for the creation
of new cellular proteins and new organelles or be additionally processed
and used as a source of energy. Moreover, autophagy may be activated
by diverse stresses, such as nutrient deprivation (caloric restriction), or
may be caused by signals arising in the course of cellular differentiation
or embryogenesis, and it can also be triggered by damaged intracellular
organelles.36 In addition, a basal level of autophagy exists that results in
Figure 1. Indirect effects of viruses on the apoptotic pathway through deregulation of cellular miRNAs
miR-2861 increased the apoptosis of cervical cancer cells through the PI3K/AKT pathway by targeting EGFR. HPV16 E6 is able to downregulate the miR-2861 expression
level and can contribute to tumor development. Moreover, HPV-16 E6/DNMT1 can suppress miR-23b expression and contribute to apoptosis resistance through the
blocking inhibitory effect of miR-23b on c-MET. EBV-LMP-1 protects B cell lymphoma from rituximab-induced apoptosis via miR-155-mediated Akt activation and upre-
gulation of Mcl-1. LMP1 can increase miR-21 to promote the resistance of nasopharyngeal carcinoma cells to cisplatin-induced apoptosis by suppressing PDCD4 and Fas-
L. HBV infection can also lead to the induction of apoptosis via the upregulation of miR-194-5p expression in vitro. miR-194-5p-mediated suppression of cFLIP expression
strongly sensitizes HepG2 cells to undergo apoptosis in response to a physiological stimulus. The transforming growth factor b (TGF-b) signaling pathway, a major inter-
cellular signaling pathway in mammalian cells, plays a key role in regulating many cellular processes, such as cell proliferation, differentiation, and apoptosis. TGF-b signaling
is known to depend on the formation of Smad2/3-Smad4 transcription regulatory complexes. EBV LMP-2A inhibits the expression level of Smad2 through regulating
miR-155-5p in gastric cancer cell lines and inhibits apoptosis. Rotavirus infection leads to up-regulation of TGF-b, which may lead to early apoptosis thus preventing virus
progression. However, rotavirus counteracts this by upregulation of miR-142-5p. Rotavirus NSP5 upregulates miR-142-5p, which targets several components of the TGF-b
signaling pathway. The mitochondrial pathway of apoptosis is dependent on the BCL-2 (B cell CLL/lymphoma 2) family of proteins for the efficient release of pro-apoptotic
factors from the mitochondrial intermembrane space. The BCL-2 family is divided into three groups based on their primary function: (1) anti-apoptotic proteins (BCL-2, BCL-
XL, BCL-W, MCL-1, BFL-1/A1); (2) pro-apoptotic pore formers (BAX, BAK, BOK); and (3) pro-apoptotic BH3-only proteins (e.g., BAD, BID, BIK, BIM). miR-503 andmiR-15a/
16 can target the 30 UTR of Bcl-2 and inhibit hepatocellular carcinoma cell growth. However, HCV NS5A and HBV mRNA decrease miR-503 and miR-15a/16 expression,
respectively, and increase Bcl-2 expression, which leads to a decrease in apoptosis.
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Figure 2. Indirect effects of viruses on the autophagy pathway through deregulation of cellular miRNAs
Autophagy involves the spatially and temporarily coordinated activation of multiple molecular components, including the ULK1 (UNC-51-like kinase 1), FIP200 (FAK family
kinase-interacting protein of 200 kDa), and ATG13–ATG101 complex, which is functionally coupled to the negative autophagy regulator, mTOR complex 1, and initiates
autophagy. The lipid kinase vacuolar protein sorting 34 (VPS34)-Beclin-1 complex is usually inactivated by anti-apoptotic proteins from the BCL-2 family, but when it is
activated it drives the nucleation of the isolation membrane.15 The AMP-activated protein kinase (AMPK)-mammalian target of rapamycin (mTOR) signaling pathway is well
known to be associated with autophagy, and AMPK can promote the initiation of autophagy. Activation of AMPK can result in the inhibition of mTOR, which is commonly
activated in malignant cells.16 miR-106a is upregulated by the HPV-16 E7 oncogene and stimulates cell proliferation and suppresses autophagy by targeting LKB1 via the
AMPK-mTOR pathway in HPV-16-associated cervical cancer. Autophagy contributes to HBV replication, as confirmed by observations that autophagy inhibition strongly
impaired replication of HBV in liver cells. The expression level of miR-155 was upregulated in HBV-infected cells, and miR-155 reinforced HBV replication by affecting the
SOCS1/Akt/mTOR-autophagy axis. HBV also promoted autophagy through themiR-192-3p-XIAP axis, which is important for HBV replication in vitro and in vivo. Beclin-1 is a
key autophagy-promoting gene in the early phase of autophagosome formation. It has been shown that EV71 infection induced autophagosome formation through the
reduction of cellular miR-30a, which led to the inhibition of Beclin-1.
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tents, as well as longer-lived proteins.37
During the initial step of autophagy, a sensor called the mechanistic
(previously mammalian) target of rapamycin (mTOR) is activated
to form complex I (mTORCI), in response to several autophagy in-
ducers. mTORCI can stimulate autophagy via initiating a signal
transduction cascade by phosphorylating selected protein compo-
nents of the autophagy machinery.38 mTORCI centrally contributes
to the modulation of the ULK1-ATG13-FIP200 (FAK family-inter-
acting protein of 200 kDa) complex, as shown by the inhibition of
mTORCI with rapamycin increasing the kinase activity of ULK1.39
Researchers have divided phosphatidylinositol 3-kinase (PI3K) en-
zymes into three different isoforms (class I, II, and III). The mTOR
signaling pathway is stimulated by class I PI3K, which also suppresses490 Molecular Therapy: Nucleic Acids Vol. 24 June 2021autophagy, whereas the class III PI3K isoform (Vps34) activates auto-
phagy. There is not enough information about class II PI3K activity
and autophagy.40 In addition, mitogen-activated protein kinase
(MAPK) signaling may activate autophagy via activation of AMPK
and consequent autophagy-associated gene translation. Therefore,
PI3K-AKT signaling suppresses autophagy by activating mTOR
and suppressing p53. Furthermore, the Vps34 complex combines
with Beclin-1 to increase autophagic cell death. However, the binding
of ATG5 to ATG12, as well as ATG16L, and phosphatidylethanol-
amine (PE) to the microtubule-related protein 1 light-chain 3
(LC3) is crucial to initiate and develop autophagy.41 Once initiated,
the autophagy process will further progress to carry out its function.
Autophagy is designed either to enhance cell survival in physiologi-
cally stressed conditions, or to provoke an alternative programmed
Figure 3. Comparison of apoptosis and anoikis
The lack of ECM contact or the engagement with inappropriate ECM leads to the activation of anoikis either by death receptors (extrinsic pathway) or mitochondria (intrinsic
pathway).
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growth factors or nutrients, autophagy ensures that cells receive
enough vital metabolic substrates, thereby compensating for the
metabolic stress imposed on the cells and enhancing cell sur-
vival.42–45 Furthermore, autophagy has been found to be induced in
cells that are detached from the extracellular matrix (ECM) in order
to avoid anoikis cell death.46 While the main function of autophagy is
the recycling of cellular contents, it can also play a role as a cell death
pathway, especially to dispose of aging cells and neoplastic cells.36
Unlike apoptotic cell death, autophagy is a reversible mechanism,
which can be reduced after elimination of the autophagy-stimulating
stress.47 However, both apoptosis and autophagy can function either
to regulate normal cell activities such as cellular homeostasis and
physiological recycling of cell contents, or else to trigger cell death
when necessary.Anoikis
Originating from a Greek word meaning homelessness, anoikis is
another type of cell death induced by the detachment of adherent cells
from the ECM (Figure 3).48 It has also been physiologically associated
with tissue homeostasis, embryonic development, and the pathogen-
esis of diseases.49–51
Anoikis can be considered to be a subset of the apoptosis mecha-
nisms,52–54 and it can also be categorized into intrinsic and extrinsic
pathways.55 As mentioned earlier, the intrinsic pathway requires cas-
pase activation due to permeabilization of the outer mitochondrial
membrane via pro-apoptotic protein members of the Bcl-2 family.56
Likewise, the extrinsic pathway involves death receptors like TNF su-
perfamily receptors, and ultimate activation of caspase-8. The two
pathways have no biological distinction because the intrinsic pathwayMolecular Therapy: Nucleic Acids Vol. 24 June 2021 491
Figure 4. Mechanism of the autophagy pathway
A series of stepwise processes, i.e., initiation, nucleation, elongation, maturation, and fusion with lysosomes, are involved in autophagy. Autophagy is induced at a basal level
under normal conditions and is further stimulated by stress, for example, by nutrient deprivation
www.moleculartherapy.org
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pathway.57,58
The initiation of anoikis depends on proteins mediating the cellular
interaction with the ECM and with neighboring cells, such as E-cad-
herin and integrins. Integrins are cell membrane receptors consisting
of two components, a and b subunits. When integrins are ligated to
their ECM receptors, they activate pro-survival signaling pathways,
such as the PI3K/Akt pathway.59 Alternatively, integrins trigger anoi-
kis and apoptosis when they adopt an unligated conformation.58 The
apoptotic response of integrins is mediated by recruiting caspase-
8.60,61 E-cadherin is a transmembrane protein with a cytoplasmic
domain that is bound to b-catenin, which then binds to a-catenin.
Because a-catenin binds to actin filaments, this complex mediates
the binding E-cadherin to the cytoskeleton, and it regulates the adhe-
sion between neighboring cells.62,63 In addition, E-cadherin can
trigger anoikis via the RAF/extracellular signal-regulated kinase
(ERK) and PI3K/Akt pathways.64,65 The loss of E-cadherin contrib-
utes to anoikis evasion in hepatocyte spheroids in the absence of
ECM.66 Hence, the loss of E-cadherin and the gain of N-cadherin
are the hallmarks of the epithelial-to-mesenchymal transition
(EMT). The EMT is characterized by the loss of anoikis, and it allows
detached cancer cells to survive long enough to produce metas-492 Molecular Therapy: Nucleic Acids Vol. 24 June 2021tasis.67,68 As mentioned above, the main factor responsible for initi-
ating anoikis is cell detachment from the surrounding ECM. The
appropriate interactions between adjoining cells and between cells
and the surrounding matrix are a key factor for the survival and dif-
ferentiation of epithelial cells. Regarded as a critical point in carcino-
genesis,69,70 anchorage-independent growth results from decreased
cell-ECM interactions, and in normal cells the resultant integrin
signaling triggers anoikis.55 Alternatively, the appropriate anchorage
between cells and matrix downregulates anoikis in normal cells.49
However, one characteristic of tumor cells is that they can circumvent
anoikis when they become detached from their ECM. Therefore, can-
cer cells can easily invade the surrounding tissues after becoming de-
tached from their primary location.51,71–73 Some virus-infected cells
have been also proven to be resistant to anoikis-mediated cell
death.74,75 For instance, anchorage-independent high-risk human
papillomavirus (hrHPV)-transformed cells avoid anoikis, probably
by inactivation of tumor suppressor genes.76
miRNAs and cell death pathways
Recently, miRNAs have become popular targets for controlling and
treating a variety of diseases. miRNAs have been applied in the clin-
ical settings as diagnostic biomarkers for several diseases, and they are
also being investigated in vaccine development.7
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tional regulators, their regulatory function has been also described
at transcriptional levels. The effects of miRNAs on the target gene
mRNA are largely dependent on the degree of complementarity be-
tween the target-gene transcriptional sequence and the sequence of
the miRNA. There are two possible scenarios. (1) When the miRNA
is fully complementary to the target gene mRNA, the function is the
same as that of small interfering RNA (siRNA) and ultimately leads to
cleavage of the target mRNA. (2) When the miRNA is not perfectly
complementary to the target gene mRNA, it can still bind and thus
inhibits translation by interfering with the mRNA stability.77
A wide variety of cellular processes have been reported to be regulated
by miRNAs, the most important of which is cell death processes
(apoptosis, autophagy, anoikis). This has been proposed to be a key
mechanism for treating several serious conditions.
Defects in the regulation of apoptosis (either too little or too much)
are involved in several human diseases, such as neurodegenerative
conditions, ischemic tissue damage, autoimmune disorders, and in
numerous types of cancer.24 Slattery et al.22 described the involve-
ment of multiple miRNAs in the process of apoptosis, both in the
intrinsic and extrinsic pathways through regulating the expression
of specific genes (extrinsic pathway genes CASP7 and BIRC5, and
intrinsic pathway genes CSF2RB and BCL2) in colorectal cancer. In
another similar study, some apoptosis-associated genes, including
BCL2 and PUMA (a Bcl-2 family member), were found to be regu-
lated by various miRNAs, such as miR-148a, miR-125b, miR-143,
andmiR-203.78–81 Furthermore, miRNAs have been reported to regu-
late other targets in apoptosis-related pathways, such as PEG10,
BTG1, ID1, interleukin (IL)-32, and NCF2.82
miRNAs can target several autophagy-related complexes, thereby
modulating autophagy at various stages, including initiation, vesicle
nucleation, elongation, and completion.83 miRNAs can regulate auto-
phagy by targeting autophagy proteins such as beclin (the first auto-
phagy protein to be discovered), or autophagy-related signaling path-
ways such as AMPK-mTOR.41 For example, miR-30a can inhibit
autophagy by downregulating beclin expression, and miR-138 can
upregulate the AMPK-mTOR pathway.84,85
Because autophagy and apoptosis share some similar intracellular
pathways involved in cellular homeostasis, they also share some up-
stream mediators, such as specific miRNAs.86,87 Studies have
confirmed the ability of certain miRNAs to inhibit both processes.
For instance, there is a physical interaction between BECN1 and
the anti-apoptotic family members (BCL2, MCL1, and BCL2L1),
which is crucial for connecting the two pathways. Under normal con-
ditions, BECN1 and anti-apoptotic BCL2 family members are capable
of binding to each other to maintain cellular homeostasis. However,
in situations where the cells are subjected to stressful conditions,
the complex between BECN1 and the BCL2 family members disasso-
ciates, increasing autophagy and suppressing apoptosis.88–90 Further-
more,MIR30A is capable of reducing the cytoplasmic level of BECN1,while numerous other miRNAs can decrease the expression of anti-
apoptotic family members, such as BCL2 and MCL1.91,92 Therefore,
miRNAs can have an active involvement in the regulation of auto-
phagy and apoptosis by altering protein-protein interactions. In addi-
tion, SQSTM1 (sequestosome-1) has been proposed to be another
mediator that is controlled by miRNAs. One study showed the ability
of SQSTM1 to modulate the polyubiquitination and aggregation of
CASP8 that is crucial for the extrinsic apoptosis pathway.93 Put differ-
ently, SQSTM1 is capable of negatively regulating the degradation of
autophagic protein LC3 via the 20S proteasome.94 The mechanism
underlying the interaction between SQSTM1 and the apoptosis and
autophagic pathways is being further investigated.
Various genes simultaneously take part in the autophagy and
apoptosis pathways, including factors such as DAPK1 (death-associ-
ated protein kinase 1), EEF2 (eukaryotic translation elongation factor
2), and some signal transduction mediators such as TP53 (p53) and
ATG5.86,95,96 Some miRNAs can exert a regulatory effect on common
targets in both apoptosis and autophagy pathways, thus regulating
both of them at the same time. MIR101, for instance, regulates a
gene shared between the two pathways, which in turn controls the
expression of RAB5A, STMN1, and ATG4D as autophagic proteins
andMCL1 as an anti-apoptotic protein.97,98 During hypoxia-reoxyge-
nation endogenous MIR204 promoted the effect of chemotherapy to
induce apoptosis via BCL2 downregulation, but it inhibited auto-
phagy through LC3-II protein modulation.99,100
Besides apoptosis and autophagy, anoikis cell death is also affected by
various miRNAs. For instance, hsa-miR-34c-3p/5p,101 hsa-miR-
203,102 and hsa-mir-129-2/-137/-3663103 were all shown to be involved
inmodulating anchorage-independent growth and therefore anoikis. It
was suggested that methylation-dependent downregulation of tumor
suppressive miRNAs played a major role in anchorage-independent
growth and in circumventing anoikis.76,103 Once the cancer cells or
the virus-infected cells are fully anchorage-independent, they may
bypass anoikis and further spread throughout the body, thereby
disseminating the disease. Moreover, several miRNAs have been
recently found to be directly associated with either the positive or nega-
tive regulation of anoikis.104 miRNA 204,105–108 miR-200c,109–111 and
miR-146a112–115 can regulate anoikis in cancer cells, whereas some
other miRNAs such as miR-10775 and miR-30a116 can perform a
similar function in virus-infected cells. Hence, a broad spectrum of
cellular mechanisms, especially cell death pathways, have been re-
ported to be regulated by miRNAs in recent decades. In this review,
we summarize the cell death-regulatory functions of miRNAs that
can be dysregulated in virus infections (Table 1).
RNA-binding proteins in virus-miRNA interactions
RNA-binding proteins are involved in the function of miRNAs in
various conditions such as viral infections. For example, flaviviruses,
which are single-stranded (ss)-positive RNA viruses, interfere with
the miRNA processing machinery by allowing the accumulation of
the non-coding (nc) subgenomic flavivirus RNA (sfRNA) that then
carries out sequestration of the double-stranded RNA (dsRNA)Molecular Therapy: Nucleic Acids Vol. 24 June 2021 493





miRNA Target of miRNA
Inhibition/ induction of
cell death Disease Sample type Ref.
HPV 16 E7 miR-27b up polo-like kinase2 inhibition of apoptosis
cervical
cancer
in vitro (SiHa and CaSki) 31
HPV 16 E7 miR-21 up – inhibition of apoptosis
cervical
cancer
in vitro (HeLa) 117
HPV 16 and
18
E6 miR-34a down – inhibition of apoptosis
cervical
cancer
human (cervical cancer tissue
samples)
in vitro (SiHa, HeLa, CaSki)
118






human (n = 57 cervical cancer tissue
samples)
in vitro (SiHa and CaSki)
119
HPV 16 E6 miR-23b down c-MET inhibition of apoptosis cervical cancer in vitro (SiHa) 120
HPV 16 E5 miR-196a down HoxB8 inhibition of apoptosis
cervical
cancer
in vitro (HeLa, SiHa) 121
HPV 16 and
18
E6, E7 miR-18a up STK4 inhibition of apoptosis
cervical
cancer
human (cervical cancer tissue
samples)
in vitro (SiHa, HeLa, CaSki, SW756,
C33A)
122
EBV EBNA2 miR-34a down PD-L1 inhibition of apoptosis Burkitt’s lymphoma
in vitro (Mutu I and Mutu III, Daudi,
Jijoye, LCL, OMA4, U2932)
123
EBV LMP2A miR-155-5p up Smad2 inhibition of apoptosis gastric cancer
in vitro (GT39, SNU719, EBVnGC,
HGC27, SGC7901)
124
EBV LMP1 miR-21 up PDCD4, Fas-L inhibition of apoptosis
nasopharyngeal
carcinoma
in vitro (C666-1 HONE1, CNE2) 125
EBV LMP1 miR-155 up UBQLN1 inhibition of apoptosis
nasopharyngeal
carcinoma
human (n = 8 radio-resistant tissue
samples of NPC)
in vitro (CNE-1, CNE-2)
126
EBV – miR-155 up – inhibition of apoptosis B cell lymphoma in vitro (EF3D, SDLCL) 32
EBV LMP1 miR-155 up PTEN inhibition of apoptosis B cell lymphoma
in vitro (SKW6.4 rituximab
resistance)
127
EBV EBNA1 miR34a down – inhibition of apoptosis gastric cancer in vitro (SNU719) 128
EBV – miR-194 down IL-10 inhibition of apoptosis PTLD




HBV HBx miR-21 up IL-12 inhibition of apoptosis HCC in vitro (HepG2.2.15) 130
HBV HBx miR-21 up
PDCD4,
PTEN
inhibition of apoptosis HCC in vitro (HepG2, Huh7) 131
HBV HBx miR-181a up PTEN inhibition of apoptosis HCC in vitro (HepG2) 132
HBV HBx miR-192-5p up BIM inhibition of apoptosis HCC in vitro (HepG2) 133
HBV HBx miR-331-3p up ING5 inhibition of apoptosis HCC
human (HCC tissue samples)
in vitro (HepG2.2.15, SMMC7721)
134
HBV HBx miR-602 up RASSF1A inhibition of apoptosis HCC
human (n = 21 HCC tissue samples)
(HepG2.2.15, HepG2-HBX)
135
HBV – miR-15a down Smad7 inhibition of apoptosis HCC
human (n = 40 HCC tissue samples)
in vitro (HepG2-4D14, HepG2-C5)/
in vivo
136
HBV – miR-30e-5p down MAP4K4 inhibition of apoptosis HCC







down Bcl-2 inhibition of apoptosis HCC
human (n = 40 HCC tissue samples)
in vitro (HepG2.2.15)/in vivo
138
HBV HBx miR-1236 down
alpha-fetoprotein
(AFP)
inhibition of apoptosis HCC
human (n = 97 tissue samples of
HCC) in vitro/in vivo
139
(Continued on next page)








miRNA Target of miRNA
Inhibition/ induction of
cell death Disease Sample type Ref.
HBV HBx miR-1270 down
alpha-fetoprotein
(AFP)
inhibition of apoptosis HCC
human (n = 97 HCC tissue samples)
in vitro/in vivo
139




down CCND1 inhibition of apoptosis HCC in vitro (SK-HEP-1, Huh7, HepG2) 141
HBV HBx miR-16 down CCND1 inhibition of apoptosis HCC in vitro (SK-HEP-1, Huh7, HepG2) 141
HBV HBx let-7 down – inhibition of apoptosis HCC
human (n = 19 HCC tissue samples)
in vitro (HepG2.2.15)
142
HBV HBx miR-193b down – inhibition of apoptosis HCC
human (HCC tissue samples)
in vitro
143
HBV HBx miR-548p down HBXIP inhibition of apoptosis HCC
human (n = 21 HCC tissue samples)
in vitro (Hep3B, HepG2.2.15)
144
HBV HBx miR-375 down AEG-1 inhibition of apoptosis HCC in vitro (SMMC-7721, HepG2-HBx) 145
HBV HBx miR-136 down AEG-1 inhibition of apoptosis HCC in vitro (SMMC-7721, HepG2-HBx 145
HBV HBx miR-192 down – inhibition of apoptosis HCC in vitro (HepG2) 146
HBV HBx miRNA-145 down CUL5 inhibition of apoptosis HCC






miR-328-3p up FOXO4 inhibition of apoptosis – in vitro (THLE-2) 148
HBV – miR-98-5p up NF-kB induction of apoptosis HCC
human (n = 30 HCC tissue samples)
in vitro (MHCC97H, Huh7)
149
HCV – miR-155 up APC inhibition of apoptosis HCC
human (n = 10 HCC tissue samples)
in vitro (Huh7)/In vivo
150
HCV core miR-345 up p21Waf1/Ci1 inhibition of apoptosis – in vitro (Huh7) 151
HCV core miR-93 up – inhibition of apoptosis – in vitro (Huh7) 151
HCV core miR-30c down – inhibition of apoptosis HCC
human (n = 152 HCC tissue samples)
in vitro (HepG2)
152
HCV core miR-203a down – inhibition of apoptosis HCC
human (n = 152 HCC tissue samples)
in vitro (HepG2)
152
HCV NS5A miR-503 down Bcl-2 inhibition of apoptosis – in vitro (HepG2) 153
HCV – miR-193b down Mcl-1 inhibition of apoptosis HCC in vitro (Hep-394) 154
HCV – miR-181c down ATM inhibition of apoptosis –




HTLV-1 Tax miR-155 up – inhibition of apoptosis ATLL in vitro (MT-2, C5/MJ, ED-40515) 156
HTLV-1 Tax miR-130b up TP53INP1 inhibition of apoptosis ATLL
human (PBMC samples of ATLL)
in vitro (MT-4)
157
HTLV-1 – miR-93 up TP53INP1 inhibition of apoptosis ATLL
human (PBMC samples of ATLL)
in vitro (MT-4)
157
Influenza A – miR-29c up BCL2L2 induction of apoptosis influenza in vitro (A549) 158
GaHV-2 Meq miR-21 up PDCD4 inhibition of apoptosis
Marek’s disease,
lymphoma
in vitro (MSB-1) 159
Rotavirus NSP5 miR-142-5p up
SMAD3,
TGFbR2
inhibition of apoptosis – in vitro (HT29) 160
HSV-1 – miR-23a up IRF1 inhibition of apoptosis – in vitro (HeLa) 161
HBV HBx miR-194-5p up cFLIP, SODD induction of apoptosis HCC in vitro (HepG2) 133
HCV – miR-200c up FAP1 induction of apoptosis hepatic fibrosis
human (n = 10 tissue samples of
HCV fibrosis)
162
(Continued on next page)








miRNA Target of miRNA
Inhibition/ induction of
cell death Disease Sample type Ref.
Influenza A
(H1N1)
– miR-34a down Bax induction of apoptosis influenza
human (n = 10 influenza serum
samples) in vitro (A549)
163
Enterovirus 71 – let-7b up CCND1 induction of apoptosis – in vitro (SH-SY5Y) 164
West Nile
virus
– Hs_154 up ECOP, CTCF induction of apoptosis – In vitro (SK-N-MC and HEK293) 165
RSV NS1 miR-24 down – induction of apoptosis – In vitro (A549) 166
HBV HBx miR-192-3p down XIAP induction of autophagy hepatitis B




HBV HBsAg miR-155 up
SOCS1/Akt/
mTOR
induction of autophagy – in vitro (HepG2, HepG2.2.15) 168
Enterovirus 71 – miR-30a down Beclin-1 induction of autophagy – in vitro (Vero, Hep2) 116
HBV – miR-224 up Smad4 inhibition of autophagy HCC human (HCC tissue samples) in vivo 169
HPV 16 E7 miR-106a up LKB1 inhibition of autophagy cervical cancer
human (n = 91 cervical cancer tissue
samples)
in vitro (SiHa, HeLa, CaSki,
HEK293T)
170
HBV HBx miR-7 up maspin inhibition of anoikis HCC
human (n = 69 HCC tissue samples)
in vitro (HepG2x, Hep3Bx,
HepG2.2.15)
75
HBV HBx miR-107 up maspin inhibition of anoikis HCC
human (n = 69 HCC tissue samples)
in vitro (HepG2x, Hep3Bx, HepG2)
75
HBV HBx miR-21 up maspin inhibition of anoikis HCC
human (n = 69 HCC tissue samples)
in vitro (HepG2x, Hep3Bx, HepG2)
75
PBMC, peripheral blood mononuclear cell.
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Reviewbinding proteins Dicer and AGO2.171 Dicer interacts with the trans-
activation response RNA-binding protein (TRBP) and the protein
activator of protein kinase R (PKR) (PACT), two dsRNA-binding
proteins that play roles in the efficiency and specificity of miRNA
processing.172
Alternatively, some miRNAs such as miR-101 also downregulate the
RNA-binding protein G-rich sequence factor 1 (GRSF1), whose bind-
ing to herpes simplex virus 1 (HSV-1) p40 mRNA typically increases
its expression, facilitating viral replication. Therefore, induction of
miR-101 expression during HSV-1 infection downregulates both
ATP5B and GRSF1 expression, consequently attenuating viral repli-
cation and preventing lytic cell death.173
It was reported that PCBP2, a member of the heterogeneous nuclear
ribonucleoprotein (hnRNP) E family of RNA-binding proteins, can
interact with a sequence-specific motif of single-stranded poly(C)
polynucleotides and is involved in the regulation of defense responses
to viruses and the negative regulation of immune effector cells.
PCBP2 could serve as a target gene of miR-HA-3p in H5N1 influenza
virus-induced uncontrolled immune responses. In addition to regu-
lating mRNA translation and maintaining mRNA stability, PCBP2
is essential for the prevention of excessive immune responses by
serving as a pivotal negative regulator in the mitochondrial antiviral
signaling protein (MAVS) signaling pathway.174496 Molecular Therapy: Nucleic Acids Vol. 24 June 2021Furthermore, the miR-17/92 cluster and miR-20a have been reported
to target the p300-cyclic AMP (cAMP)-responsive element binding
protein (CREB)-binding protein-associated factor (PCAF) and
render the cells less susceptible to HIV-1 infection. It is known that
PCAF has a role in tat acetylation, and acetylated tat is transcription-
ally more active.81 Alternatively, HIV-1 tends to suppress these miR-
NAs and upregulate PCAF expression, leading to a possible increase
in viral infectivity.175,176
Viruses have had ample time to evolve in ways that prevent the binding
of RNA-induced silencing complexes (RISCs) programmed by cellular
miRNAs, leading to their destruction. The rapid loss of cognate RISC-
binding sites has been observed when rapidly evolving viruses such as
HIV-1 are grown in the presence of artificial siRNAs, which function in
a similar manner to miRNAs when they bind to perfectly complemen-
tary RNA targets.177,178 Moreover, viral gene products that block RISC
function are common in plants and insect viruses, where RNAi repre-
sents a major innate immune response to viral infection. It remains un-
clear whether viruses that infect mammals, which do not mount an
innate RNAi response to viral infection of somatic cells, commonly
encode inhibitors of miRNA biogenesis.179
Therapeutic potential of miRNAs in virus infections
miRNAs are involved in the regulation of almost all physiological
processes, such as cell development, differentiation, proliferation,
www.moleculartherapy.org
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new biomarkers for diagnosis and in therapeutic approaches for viral
infections. To date, more than 1,000 different human miRNAs have
been identified, and it is predicted that miRNAs control the expres-
sion of approximately 60% of all human genes.180 Recently, new
methods and tools have been developed for the detection and quan-
tification of virus-regulated miRNAs. For example, the use of multi-
plexed qRT-PCR, microarrays, or next-generation sequencing
(NGS)-based genome-wide approaches have helped to provide
expression profiles of large numbers of miRNAs.181 Moreover, bioin-
formatics approaches and existing databases have enabled the discov-
ery of thousands of miRNAs in viruses, e.g., Vir-Mir db, BiTargeting,
and ViTa.182
The aberrant expression of miRNAs has been linked to the initiation
and progression of virus infections. Some miRNAs have been demon-
strated to be involved in the pathogenesis of viral diseases, e.g., mir-
122 and mir-21 in hepatitis C virus (HCV), and mir-507 and mir-
136 in influenza.183
Furthermore, the structure and quantity of miRNAs contained within
exosomes secreted from virally infected and non-infected cells are
different.184 Therefore, miRNAs could provide a new approach for
better clinical decision-making. Moreover, miRNAs carry out potent
and specific gene silencing, making them attractive therapeutic tools.
To date, most efforts in this setting have been to explore the potential
application of miRNA therapeutics for viral infections.185
However, some challenges faced by the use of miRNAs as therapeutic
tools include: (1) degradation by nucleases after introduction into
biological systems, (2) poor cell membrane penetration, (3) entrap-
ment in endosomes, (4) insufficient binding affinity for complemen-
tary sequences, (5) inadequate delivery to desired target tissues, (6)
off-target effects and unwanted toxicity, and (7) activation of innate
immune responses.186 Despite these limitations, future research could
improve the miRNA properties to overcome these challenges. For
example, improvements in miRNA delivery are being addressed by
chemical modifications and applications of nanotechnology.186
INDIRECT REGULATION OF THE APOPTOSIS
PATHWAY IN VIRAL INFECTIONS BY CELLULAR
miRNAs
A vast array of virus-related miRNAs have been found to be involved
in the modulation of cellular apoptosis.
HBV
Several miRNAs are known to participate in the life cycle of HBV
infections.187 HBV causes acute and chronic hepatitis in humans,
and it has become a serious health issue affecting 240 million indi-
viduals worldwide.188,189 Epigenetic modifications occurring in HBV
infection increase the expression of miR-1 and miR-449a and in
turn increase the expression of the nuclear receptor farnesoid X re-
ceptor a (FXRa), which stimulates the core HBV promoter function
as well as HBV replication.190,191 Moreover, miR-373 and miR-372are capable of upregulating HBV gene expression via the nuclear
factor (NF)-kI/B axis.192 It was found that the miR-122 levels
were negatively correlated with intrahepatic viral load, hepatic ne-
crosis, and inflammation. The depletion of endogenous miR-122
by its antisense inhibitor led to enhanced HBV replication, whereas
overexpression of miR-122 by transfection using a mimic or an
expression vector inhibited viral production. miR-122 can have an
indirect effect on HBV replication via repression of the expression
of its target cyclin G1, thereby inhibiting the binding of p53 to cy-
clin G1 and abrogating the p53-regulated suppression of HBV repli-
cation. Therefore, miR-122 can act as a host restriction factor in
HBV infection, and its downregulation during HBV infection might
contribute to viral persistence. Therefore, the induction and increase
of miR-122 expression could provide an effective strategy for treat-
ment of HBV infection and related liver diseases.192 In contrast,
miR141 could downregulate HBV replication by targeting the
peroxisome proliferator-stimulated receptor-a (PPARA). Hence,
miR-141 could suppress HBV replication by reducing HBV pro-
moter activity by downregulating PPARA. PPARA may be a prom-
ising host-oriented drug target for the development of novel HBV
treatment, which could be mediated by miRNAs.193 miR-130a tar-
gets two metabolic modulators, peroxisome proliferator-stimulated
receptor-g and its respective co-activator PGC1-a, thereby prevent-
ing replication of HBV.194 miRNAs are important regulators in viral
infections, which could provide an effective strategy for treatment of
HBV infection and related diseases.
Aquaporins (AQPs) are membrane water transport channels that
contribute to water secretion and adsorption in epithelial cells. A
number of aquaporin subtypes can transfer other molecules, such
as urea and glycerol. At present, there are 13 specific types of AQPs
in mammals that are principally divided into three groups:195,196
(1) classical AQPs that are the original water-selective channels,
including AQP0, AQP1, AQP2, AQP4, AQP5, AQP6, and AQP8;
(2) aquaglyceroporins such as AQP3, AQP7, AQP9, and AQP10
that are capable of transporting glycerol and other small solutes;
and (3) non-classical AQPs such as AQP11 and AQP12 that are
located inside the cells. Nonetheless, researchers have not yet reached
a complete understanding of their selectivity. Currently, the contribu-
tion of the AQPs to tumor progression is increasingly being investi-
gated. Earlier investigations showed strong expression of the AQPs
in tumor cells from various origins that were proposed to contribute
to tumor-related edema, tumor cell migration, proliferation of tu-
mors, as well as tumor angiogenesis.197,198 In addition, the expression
of AQPs in various types of tumors is different due to the respective
tissue-specific localization. Furthermore, the expression of AQP5 is
upregulated in colon cancer tissues.
Zhang et al.199 addressed the role of miR-325-3p and AQP5 in the
proliferation and apoptosis of HBV-infected hepatocellular carci-
noma (HCC) cells. The results showed that miR-325-3p directly tar-
geted AQP5 and decreased mRNA and the protein level of AQP5 that
increased proliferation and inhibited apoptosis in HCC cells. Overex-
pression of miR-325-3p further inhibited proliferation and inducedMolecular Therapy: Nucleic Acids Vol. 24 June 2021 497
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and induced apoptosis in Huh7-1.3 and HepG2.2.15 cells via a direct
decrease of AQP5 expression. Moreover, silencing the AQP5 expres-
sion duplicated the pro-apoptotic impact of miR-325-3p overexpres-
sion. HBV downregulates miR-325-3p and suppresses AQP5, result-
ing in inhibition of apoptosis and contributing to tumor
progression.199 Therefore, AQPs may be a promising drug target
for the development of a novel HBV therapy that uses miRNAs.
Avian leukosis viruses (ALVs)
ALVs are a type of avian retroviruses that can induce tumors in
chickens.200 Chicken ALVs are categorized into six subgroups (A–E
and J) with regard to the envelope glycoprotein that is responsible
for the viral entry and is involved in host virus neutralization.201,202
During recent years, ALV-J has become epidemic in nature and af-
fects commercial egg layers and local breeding flocks in China.203
Moreover, ALV-J causes myeloid leukosis and creates more severe
problems in comparison to other virus subgroups.204 Studies have
shown that ALV-J and other subgroups are among the leading causes
of avian infections205–207 and can also cause immunosuppression by
inhibiting dendritic cells (DCs).208 DCs are a type of professional an-
tigen-presenting cells (APCs) that have multiple subtypes with
different functions. DCs are capable of promoting an immune
response in the presence of tissue damage signals or pathogens, and
also inducing and maintaining immune tolerance.209 Moreover,
DCs have been proposed to be the master regulators and initiators
of the immune responses that link innate and adaptive immu-
nity.210,211 In addition, their existence is crucial for maintaining im-
mune homeostasis and preventing autoimmune responses to self-an-
tigens.210 However, their function relies on suitable DC maturation
that is often modulated by miRNAs.212–215
The ALV provirus, as a retrovirus, is capable of random integration
into the host genome that possibly leads to the deregulation of gene
expression, in particular the expression of diverse regulatory factors
such as miRNAs.216 Moreover, there is insufficient information about
the mechanism of the ALV provirus integration, and ALV integration
is frequently random. Nonetheless, a number of investigations have
shown the integration of the provirus into specific sites upstream of
some oncogenes (e.g., c-erb, c-myc, TERT, EGFR, MET,
ZIC1).217,218 Therefore, ALV integration may modulate the expres-
sion of some miRNAs by unclear mechanisms. In addition, the pro-
cess of virus infection, as well as replication, triggers the cells to alter
their miRNA expression. Because some miRNAs, such as miR-146a
and miR-146b, are responsible for DC apoptosis,219 the immunosup-
pressive effect of ALV-J on DCs may be attributed to the regulation of
miRNAs involved in apoptosis pathways.
Liu et al.220 explored the miRNA-mediated apoptotic effects of ALV
infection on cultured DCs in vitro. Based on their findings, ALV-J was
shown to be capable of infecting the cells in the initial phases of dif-
ferentiation, and infection with ALV-J caused apoptosis in the DCs.
Moreover, miRNA sequencing of the non-infected and infected
DCs showed 122 differentially expressed miRNAs, of which 115498 Molecular Therapy: Nucleic Acids Vol. 24 June 2021were upregulated following ALV-J infection, and 7 miRNAs showed
considerable downregulation. The miRNAs exhibiting the most upre-
gulation were proposed to affect nutrient processing as well as meta-
bolic functions. Therefore, ALV-J infection of the chicken DCs was
capable of inducing apoptosis through altered miRNA expression,
providing the motivation for additional study of the epigenetic effects
of ALV-J-induced immunosuppression. Therefore, aberrant miRNA
expression caused by ALV-J infectionmay interfere with DC differen-
tiation and apoptosis, resulting in defective antigen presentation and
suppression of the immune response.220
Chikungunya virus (CHIKV)
CHIKV is a re-emerging infectious disease caused by an alphavirus,
resulting in large-scale outbreaks in the islands of the Indian Ocean,
Southeast Asia, and currently in the Caribbean region.221–223 More-
over, CHIKV causes symptoms of debilitating arthritis that can
endure from 1 week up to a year.224,225 CHIKV can infect both pe-
ripheral tissue as well as the central nervous system (CNS), which is
most serious in newborns and children, and even in adults.225 For pe-
ripheral infections, CHIKV virus can affect the connective tissue of
the joints, fibroblast cells of the dermis, as well as the muscle fascia.
In addition, CHIKV induces delayed apoptosis in infected cells, and
it uses the apoptotic blebs for spreading the infection to the neigh-
boring cells.226–228 However, further studies are needed to fully inves-
tigate the CHIKV-mediated molecular pathways in fibroblasts.222,224
Sharma et al.229 carried out an investigation on the regulation of miR-
NAs in mouse fibroblast cells immediately following infection in or-
der to identify the pathways targeted by CHIKV. In the next step, the
researchers analyzed the expression of 760 separate miRNAs at 6 h
after infection with CHIKV. Bioinformatic analysis was used to iden-
tify the signaling pathways that were targeted by the highly altered
miRNAs. A singleplex miRNA assay was used to validate the miR-
NAs, and then western blot analysis was used to confirm the protein
targets of the miRNAs. Among the 760 miRNAs studied, it was found
that 75 miRNAs were significantly regulated following CHIKV infec-
tion, and of these 71 were upregulated in the infected cells. According
to the functional pathway and network analysis, the miRNAs that
were most altered contributed to apoptosis and signaling pathways,
such as Toll-like receptors (TLRs), the PI3K/Akt pathway, mTOR,
and JAK-STAT, that were proposed to be involved in the course of
CHIKV infection. Finally, topoisomerase Iib was one target of the
two downregulated miRNAs in CHIKV infection. Several miRNAs
have been shown to be involved in processes that occur later after
CHIKV infection, such as cellular proliferation, immune response,
and apoptosis, which may be useful for treatment of CHIKV infec-
tions in the future.229
Influenza A virus (IAV)
IAV is one of the most common enveloped negative strand RNA
viruses in the Orthomyxoviridae family. The IAV genome contains
eight RNA sequences, with two of them encoding major surface
glycoproteins known as neuraminidase (NA) and hemagglutinin
(HA). By analysis of its antigenicity, this virus may be divided
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However, researchers have found a large number of permutations
containing various HA and NA subtypes.230 Based on the virus
strain, different IAVs have different pathogenicity for infection.
For instance, less pathogenic avian influenza viruses (LPAIVs)
result in only mild respiratory symptoms that can be occasionally
followed by a gastrointestinal infection. Alternatively, the highly
pathogenic avian influenza viruses (HPAIVs) such as H7N9 and
H5N1 lead to multiorgan systemic infections, as well as fatal ill-
nesses.231 Overall, IAV infections annually account for nearly
500,000 deaths throughout the world, and they also cause high
rates of death in several animal species.232 The key clinical charac-
teristic is the severity of pneumonia that manifests as cough, fever,
and difficulties in breathing. Even though some investigations have
shown that IAV can affect cell apoptosis in vitro and
in vivo,158,233,234 there is not enough information about the respec-
tive molecular mechanism(s).
IAV infection is capable of altering miRNA expression in animal
models as well as in cultured cells.235–238 It is known that specific
miRNAs are capable of positively or negatively influencing the im-
mune response,239–242 and some individual miRNAs can control
apoptosis induced by virus infection by targeting cellular mRNAs
and protein levels.158 Furthermore, changes in miRNA expression
following viral infection profoundly influence the innate host
response to viral infection. Nevertheless, the effects of miRNAs on
cell apoptosis after IAV infection have been less well studied.
In one study, Fan and Wang243 addressed the molecular mechanism
of miR-34a in IAV-induced apoptosis. They used a miRNA array to
identify the miRNAs involved in IAV infection, and western blotting
and a luciferase reporter assay to determine the target gene of miR-
34a. After that, they transfected a miR-34a mimic into the IAV-in-
fected A549 cells and examined the changes in target gene expression.
According to the results, miR-34a was considerably downregulated in
IAV-infected A549 cells, as confirmed by quantitative reverse tran-
scriptase PCR (qRT-PCR) in vivo and in vitro. Afterward, transfection
with a miR-34 mimic or an inhibitor in the IAV-infected A549 cells
confirmed the effects on apoptosis. It was predicted that miR-34a
was complementary to the 30 UTR of the mRNA for Bax, and western
blotting and a luciferase reporter assay confirmed the direct targeting
of Bax by miR-34a. Western blotting showed that the upregulation of
the Bax protein level was reversed by miR-34a overexpression. They
proposed that miRNAs could provide therapeutic targets for influ-
enza virus infections.243
INDIRECT REGULATION OF THE AUTOPHAGY
PATHWAY BY CELLULAR miRNAs IN VIRAL
INFECTIONS
It has been found that autophagy contributes to the interactions be-
tween host cells and viruses. In the course of viral infection, auto-
phagy is capable of performing either a proviral or an antiviral func-
tion. Autophagy can act as an anti-viral defense mechanism of the
innate immune system, because it can lead to the preferential degra-dation of the sequestered viral structures within the cells to inhibit vi-
rus replication.244–246 It has been proposed that several viruses, such
as poliovirus, coronaviruses, enteroviruses, DENV, and HCV, can all
subvert the autophagy mechanism to promote their respective repli-
cation.116,247–250 Autophagy has been found to have a role in the regu-
lation of virus replication, and it also directly affects the generation of
some inflammatory cytokines. Disrupting the normal autophagy
pathways considerably increases the secretion of the proinflammatory
cytokines IL-1b, IL-18, and IL-1a.251–253 The treatment of human
and murine cells with the autophagy inhibitor 3-methyladenine (3-
MA) largely suppressed the TLR-dependent secretion of IL-6 and
TNF-a.254 Moreover, silencing of ATG7 decreased the generation
of TLR-dependent IL-8 in intestinal epithelial cells.255 Autophagy
also contributes to the regulation of type I IFN secretion. Recently
it was shown that knockdown of either ATG7 or Beclin-1 increased
the expression of IFN-a and IFN-b in HCV infected immortalized
human hepatocytes (IHHs).256 The innate immune system is affected
by autophagy, and how this affects the virus-host cell interaction re-
quires further investigation. Herein, we summarize the existing
knowledge about the miRNAs that regulate autophagy in virus-in-
fected cells.
HBV and autophagy
Intracellular pathways, inflammatory cytokines, specific hormones,
and other factors are known to be involved in the regulation HBV
replication.257–260 miRNAs have been found to be involved in the
intracellular pathways modulating HBV transcription through
regulation of transcription factors, nuclear receptors, and other
gene products.261 miR-101 was found to repress the HBV replica-
tion via targeting the forkhead box O1 (FOXO1) transcription fac-
tor.262 miR-449a accelerated HBV replication via targeting CREB5,
which in turn induced the expression of FXRa, a transcription fac-
tor known to facilitate HBV replication. CREB5 knockdown and
overexpression confirmed that it was a negative regulator of
HBV replication. Additionally, miR-449a overexpression inhibited
proliferation, caused cell cycle arrest, and promoted HCC cell dif-
ferentiation. The results indicated that epigenetically regulated
miR-449a targeted CREB5 to increase FXRa expression, thereby
promoting HBV replication and gene expression.190 Moreover,
miR-224, miR-138, miR-224, miR-576, and miR-596 directly tar-
geted the pre-genomic RNA (pgRNA) of HBV and inhibited virus
replication. It has been proposed that in the early phase of HBV
infection, HBx binding at or near to the p65/NF-kB sites within
the miR-224 promoter leads to the repression of miR-224 expres-
sion and inhibits viral replication. However, inactivation of HBx
leaves the miR-224 promoter free to respond to the TNF/LT-
NF-kB signaling in HCCs, leading to the formation of highly
dysplastic nodules.263 Nevertheless, this hypothesis remains to be
confirmed in vivo.
The PI3K/Akt signaling pathway has been proposed to be a key
cellular pathway in the regulation of HBV infection.264,265 In addition
to the effects of apoptosis discussed in the previous section, autophagy
is also involved in the regulation of HBV infection.266,267 IAV, HIV,Molecular Therapy: Nucleic Acids Vol. 24 June 2021 499
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their replication.250,268–271 Autophagy is thought to be modulated
by the PI3K/Akt/mTOR pathway, which could facilitate HBV infec-
tion. For instance, autophagy was found to be increased by suppress-
ing mTOR activity in eukaryotic cells.272,273
Zhang et al.274 investigated the role of miR-155 in HBV replication as
well as the possible involvement of autophagy in this process. More-
over, downregulation of miR-155 increased HBV infection, while
miR-155 transfection increased antigen expression, HBV replication,
and progeny secretion in HepG2.2.15 cells. Additionally, miR-155
contributed to the suppressor of the cytokine signaling 1 (SOCS1)/
Akt/mTOR axis and reinforced autophagy in HepG2.2.15 cells. Addi-
tionally, the autophagy inhibitor (3-MA) abolished the hepatitis B
surface antigen (HBsAg) secretion triggered by miR-155. Hence,
miR-155 helped HBV replication via reinforcing SOCS1-stimulated
autophagy. It was proposed that chronic HBV could be treated or
ameliorated by inhibiting miR-155 in the cells, and autophagy inhib-
itors (3-MA) could also be tested.274
Lin et al.275 examined whether the miR-99 family modulated HBV
replication and investigated the underlying molecular mechanism.
The expression of the miR-99 family was downregulated in hepatoma
cells, in comparison to primary hepatocytes. Transfection of miR-
99b, miR-100, and miR-99a enhanced HBV replication, antigen
expression, and progeny secretion in hepatoma cells. Nonetheless,
the miR-99 family did not influence HBV transcription or the activity
of the HBV promoter, suggesting that these miRNAsmodulated HBV
replication at the post-transcriptional stage. In agreement with bio-
informatic analysis, it was found that ectopic expression of the
miR-99 family reduced the insulin growth factor (IGF)-1R/Akt/
mTOR pathway signaling and suppressed insulin-stimulated activa-
tion in hepatoma cells. The miR-99 family increased autophagy via
mTOR/ULK1 signaling and increased HBV replication.
Several miR-29 members, such as miR-29a, miR-29b, miR-29c, miR-
29d, and miR-29e, have shown an anti-viral activity. Overexpression
of miR-29c in HepG2.2.15 cells efficiently repressed the expression of
TNF-a-induced protein 3 and inhibited HBV DNA replication. miR-
29c overexpression suppressed proliferation and induced
apoptosis.276 HCV infection downregulated miR-29, and the overex-
pression of miR-29 decreased the level of HCV RNA in hepatic stel-
late cells. HCV infection downregulates miR-29 in hepatocytes, and
this may explain the increase in collagen synthesis by reducing the
miR-29 levels in activated hematopoietic stem cells (HSCs). It is
possible that treatment with a miR-29 mimic in vivo may suppress
HCV and decrease fibrosis.277 Many studies have shown a correlation
between the occurrence of fibrosis in different organs such as kid-
ney,278 heart,279 and liver280 with members of the miR-29 family.
Duck enteritis virus (DEV) and autophagy
DEV is the causative pathogen of duck viral enteritis disease that
causes significant economic losses in the duck farming industry, re-
sulting in the death of the birds and in lower egg production.281,282500 Molecular Therapy: Nucleic Acids Vol. 24 June 2021Additionally, DEV may lead to morbidity and mortality in swans,
geese, and wild waterfowl, and it is considered a serious threat to
waterfowl species.283–285
Wu et al.286 examined the possible role of miR-30a-5p in DEV infec-
tion. They used qRT-PCR tomeasure Beclin-1 mRNA expression and
levels of miRNAs (miR-30a-5p). Researchers used a dual-luciferase
reporter assay (DLRA) to determine miR-30a-5p-Beclin-1 target
interaction and western blotting to analyze Beclin-1 expression and
autophagy in duck embryonic fibroblasts (DEFs). Moreover, the me-
dian tissue culture infective dose (TCID50) was calculated to estimate
DEV titers. The results showed considerable downregulation of miR-
30a-5p and remarkable upregulation of Beclin-1 mRNA in the DEV-
infected DEFs. In addition, a DLRA verified the direct targeting of the
30 UTR of the Beclin-1 gene by miR-30a-5p. Overexpression of miR-
30a-5p decreased the level of Beclin-1 protein expression and Beclin-
1-mediated autophagy, and it eventually repressed DEV replication.
Alternatively, transfection of a miR-30a-5p inhibitor increased Be-
clin-1-mediated autophagy and stimulated DEV replication over
the entire course of DEV infection. It was concluded that miR-30a-
5p was capable of inhibiting DEV replication via reduction of auto-
phagy by targeting Beclin-1. This approach could be a new anti-viral
treatment strategy against DEV infection.286
DENV and autophagy
Dengue is a common arthropod transmitted viral disease in tropical
and subtropical areas of the world.287 In DENV infections, the patient
can either suffer from dengue shock syndrome (DSS) and serious
dengue hemorrhagic fever (DHF) or self-limiting dengue fever
(DF).287 Researchers have considered cell autophagy to be necessary
for efficient DENV replication.116,288–290 Autophagy is involved in
DENV replication via alterations in cellular lipid metabolism that in-
crease the generation of the ATP required for DENV replication.291
Most investigations have been carried out in liver cell lines, such as
Huh7 and HepG2. However, other studies have given contradictory
results, showing that the induction of autophagy decreased the
DENV2 yield in the monocytic cell line U937.292 Consequently, the
effects of autophagy on DENV replication appear to be mediated in
a cell type-specific manner and require further work to understand
the full implications.
miR-146a has already been shown to play a role in DENV replication
inside monocytes via affecting the TRAF6 innate adaptormolecule.293
Pu et al.294 reported a new contribution of miRNA miR-146a to the
negative regulation of cellular autophagy in DENV-infected A549
cells and THP-1 cells. Results showed that overexpression of miR-
146a blocked DENV2-induced autophagy and, conversely, that
locked nucleic acid (LNA)-mediated suppression of miR-146a abro-
gated these effects. In addition, overexpression of TRAF6, which is
a target of miR-146a, reversed the suppressive effect of miR-146a
on autophagy. Furthermore, treatment with recombinant IFN-b fully
restored the autophagy activity in the TRAF6-silenced cells. In
DENV2-infected A549 cells, autophagy enhanced the pro-inflamma-
tory response with increased production of TNF-a and IL-6. It was
www.moleculartherapy.org
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autophagy and that TRAF6 was a main target of this miRNA in the
modulation of DENV autophagy.294
Bovine viral diarrhea virus (BVDV) and autophagy
BVDV is an enveloped, positive sense ssRNA virus belonging to the
genus Pestivirus in the Flaviviridae family.295 BVDV causes multiple
diseases in cattle, such as hemorrhagic syndrome, diarrhea, respira-
tory disorders, reproductive disorders, mucosal disease, and persis-
tent infections, which cause considerable economic losses to the cattle
industry.296 Moreover, infection with the BVDV strain NADL
considerably induced autophagy in Madin-Darby bovine kidney
(MDBK) cells and enhanced the level of expression of two auto-
phagy-associated genes, ATG14 and BECN1. In addition, the initial
phases of autophagy were involved with BVDV NADL replication
in MDBK cells.297
Fu et al. examined whether the Bos taurus (cattle) bta-miR-29b was
upregulated in MDBK cells after infection with the BVDV strain
NADL.298 Six hours after infection, the miR-29b level in infected cells
was found to be 2.3-fold higher compared to normal cells. The auto-
phagy process in BVDV NADL-infected cells was significantly in-
hibited by lentivirus-induced upregulation of miR-29b via direct tar-
geting of ATG14 and ATG9A, two major autophagy-related proteins.
The results were confirmed by overexpression of ATG14 and ATG9A
leading to upregulation of autophagy and increased BVDV NADL
replication. BVDV NADL replication was induced in MDBK cells
during the early stages of autophagy, and it was inhibited after sup-
pression of autophagy. It was concluded that there was a new connec-
tion between viral replication and miR-29b.298
INDIRECT REGULATION OF THE ANOIKIS PATHWAY
BY CELLULAR miRNAs AFTER VIRUS INFECTION
As discussed above, once metastatic cancer cells are detached from
the ECM, they become resistant to anoikis cell death, thereby pene-
trating into the lymph and blood circulation.299,300 Tropomyosin 1
(TPM1) has mostly been studied as a tumor suppressor gene, which
inhibits the transformed phenotype and reduces anchorage-inde-
pendent growth. In addition, TPM1 downregulation led to inhibi-
tion of anoikis in breast cancer cells.301–303 Interestingly, high mo-
lecular weight (HMW) TPM1 was downregulated by high levels
of oncomir hsa-miR-2 in transformed cells.304,305 The HMW forms
of TPM1 and TPM2 undergo translocation to the endothelial cell
surface when activated by growth factors such as vascular endothe-
lial cell growth factor (VEGF) or basic fibroblast growth factor
(bFGF). A variety of ligands, including histidine-proline-rich glyco-
protein (HPRG),306,307 cleaved HMW kininogen (HKa),308,309 and
endostatin310 can then bind to TPMs on the cell surface, acting as
their receptors. The anti-angiogenic effects of such binding can be
abrogated by administration of engineered antibodies against the
TPM1 and TPM2 cell surface receptors.311 Therefore, TPM1 can
not only stabilize actin stress fibers in favor of anti-angiogenesis,
but it can also promote anoikis301 and inhibit cancer development
in primary breast tumor cells.302Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV) and
anoikis
KSHV causes the vascular hyperplasic disease KS by infecting endo-
thelial cells.52,312,313 KSHV may also infect B lymphocytes and
contribute to the multicentric lymphoproliferative condition called
Castleman’s disease,314 or to primary effusion lymphoma.315 It was
found that endothelial cells that have been infected by KSHV undergo
malignant transformation with a higher angiogenic activity.312,313
KSHV has been shown to be in the latent phase in most KS cells,
which only express a limited number of viral proteins, but there are
18 mature KSHV miRNAs derived from 12 precursor (pre-)miR-
NAs.316 Some targets of KSHV miRNAs (miR-Ks) have been identi-
fied.317–319 In the course of KS, a major rearrangement of the host
cytoskeleton is observed,320 and two gene expression microarray as-
says were used to show that cytoskeleton TPM1 was downregulated
in KSHV infection of telomerase-immortalized microvascular endo-
thelial (TIME) cells or lymphatic endothelial cells (LECs).321,322
Because anoikis is inhibited by TPM1 downregulation in breast can-
cer cells,301 and also by KSHV-induced expression of vFLIP,323 it is
proposed that KSHV-infected cells show partial resistance to anoikis
cell death.
Kieffer-Kwon et al.74 examined whether the HMW TPM1 isoforms,
which they showed to be downregulated by two KSHV miRNAs
(miR-K2 and miR-K5), were able to suppress anoikis. They detected
a functional binding site for miR-K5 in the 30 UTR of one TPM1 iso-
form. Although KSHV-infected cells showed relatively higher levels
of TPM1 protein compared to normal cells, these infected cells ex-
pressed even higher levels of TPM1, once miR-K2 or miR-K5 was
downregulated. Mechanistically, miR-K2/miR-K5-induced downre-
gulation of TPM1 isoforms increases VEGFA expression and tube
formation from non-anchored human umbilical vein endothelial cells
(HUVECs), and it increases the survival rate of HUVECs via sup-
pressing anoikis. Overall, it was concluded that miR-K2 and miR-
K5 were probably involved in the development of KSHV
pathogenesis.74
HBV and anoikis
HCC is a complex and heterogeneous disease caused by different risk
factors, including viral infections. When HCC undergoes an invasive
transformation, it leads to metastasis, post-surgical recurrence, and
poor response rates to chemotherapy, with a corresponding poor
prognosis and lower survival rate.324,325 HCC may be caused by
HBV infection, because DNA repair, cell cycle progression, cellular
adhesion, transcription modulation, signal transduction, and
apoptotic pathways are all regulated by the small open reading frame
of the HBV genome, HBV X protein (HBx).326–329 HBV can activate
cellular oncogenes, promote genome instability, regulate the host im-
mune response, and facilitate other oncogenic processes, and there-
fore HBV is considered to be a major carcinogenic virus.330
A member of the serine protease inhibitor (serpin) superfamily,
named mammary serine protease inhibitor (maspin) or serpin B5,
is highly expressed in normal epithelial cells but is down-expressedMolecular Therapy: Nucleic Acids Vol. 24 June 2021 501
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associated with angiogenesis, tumor growth, and tumor cell migra-
tion.332–335 Maspin also upregulates integrin expression, thus pro-
moting cell-fibronectin binding and reducing metastasis.335 Several
studies have shown that maspin is downregulated in HCC cell
lines;336–339 however, the role of maspin in HCC development is
not fully understood.
Chen et al.75 explored the pathway by which HBV-infected HCC cells
could regulate maspin expression, as well as the secondary effects of
this regulation. In accordance with previous studies, HCC cells ex-
hibited a lower level of maspin expression. Mechanistically, miR-7,
miR-21, and miR-107 were found to be upregulated by HBx, which,
in turn, resulted in maspin downregulation. Moreover, analysis of pa-
tient samples showed a relationship between increased expression of
miRNAs and maspin downregulation in HBV-infected HCC patients
that was also linked to poor overall survival. The cancer cell resistance
to anoikis, tumor metastasis, and chemoresistance were all enhanced
by HBx-induced maspin downregulation. In addition, overexpression
of maspin mediated by a lentivirus enhanced the sensitivity of the
HBx-expressing HCC cells to anoikis, as well as increasing their
viability. The data showed that downregulation of maspin via miR-
NAs is involved in the HBx-mediated malignancy and chemoresist-
ance in HCC.75
CONCLUSIONS
Viral pathogens are a major threat to public health, either by directly
causing viral infections or being responsible for several cancer types.
The underlying mechanism explaining how viruses affect different
cellular functions is of great importance. One of the most critical
cell functions affected by viruses is programmed cell death, which
has repeatedly been shown to be mediated by several miRNAs.
miRNA-dependent regulation of cell death pathways has proved to
be a complex yet crucial issue, with more and more miRNAs having
been found to be involved in both positive and negative regulation of
these pathways. In this review, we summarized the available data on
the virus-regulated miRNAs that modulate cell death pathways, and
that can be used for further development of diagnostic and therapeu-
tic techniques.
As shown in Table 1, several miRNAs, such as miR-155, miR-34a,
miR-193b, and miR-93, have been reported to be regulated by various
viruses. For instance, miR-21 was upregulated by several different vi-
ruses, such as HBV, EBV, and GaHV-2. Nevertheless, its target, the
tumor suppressor PDCD4, was the same regardless of the virus
type. However, it was reported that miR-21 regulated by the same
HBV had different targets in each study (e.g., PDCD4, PTEN, IL-
12, maspin, Fas-L). It can also be concluded that the same miRNAs
often participate in the regulatory pathways that affect different types
of cell death. For instance, the upregulation of miR-21 by HBV led to
the inhibition of both apoptosis and anoikis. HBV led to the downre-
gulation of miR-192-3p and the upregulation of the closely related
miR-192-5p; the former enhanced autophagy while the latter in-
hibited apoptosis. This may be due to the presence of connections be-502 Molecular Therapy: Nucleic Acids Vol. 24 June 2021tween different cell death pathways, which has already been shown.
Most intriguingly, the regulation of cell death pathways by specific
miRNAs was found to be different depending on the type of virus.
For instance, miR-34a downregulation by HPV 16 and HPV 18 led
to inhibition of apoptosis, whereas miR-34a downregulation by
H1N1 produced the opposite result. In other words, apoptosis could
result from both upregulation and downregulation of miR-34a, de-
pending on the type of host cell and viral pathogen.
Overall, the miRNAs that are involved in the modulation of cell death
pathways after virus infection show a degree of complexity and a va-
riety of functions. Further studies are required to fully understand the
complex pathways and functional targets before any therapeutic ap-
plications can be tested.
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